Klos KS - Search Results

1

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. Nagata Y, et al. Among authors: klos ks. Cancer Cell. 2004 Aug;6(2):117-27. doi: 10.1016/j.ccr.2004.06.022. Cancer Cell. 2004. PMID: 15324695 Free article.

2

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.

Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Klos KS, et al. Cancer. 2003 Oct 1;98(7):1377-85. doi: 10.1002/cncr.11656. Cancer. 2003. PMID: 14508823 Free article.

3

Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer.

Klos KS, Yu D. Klos KS, et al. Cancer Biol Ther. 2004 Feb;3(2):205-6. doi: 10.4161/cbt.3.2.714. Epub 2004 Feb 1. Cancer Biol Ther. 2004. PMID: 14764991 Free article. No abstract available.

4

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Zhou X, et al. Among authors: klos ks. Clin Cancer Res. 2004 Oct 15;10(20):6779-88. doi: 10.1158/1078-0432.CCR-04-0112. Clin Cancer Res. 2004. PMID: 15501954

5

ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.

Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. Tan M, et al. Among authors: klos ks. Cancer Res. 2005 Mar 1;65(5):1858-67. doi: 10.1158/0008-5472.CAN-04-2353. Cancer Res. 2005. PMID: 15753384

6

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.

Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. Klos KS, et al. Cancer Res. 2006 Feb 15;66(4):2028-37. doi: 10.1158/0008-5472.CAN-04-4559. Cancer Res. 2006. PMID: 16489002 Free article.

7

Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Lee S, et al. Cancer Res. 2002 Oct 15;62(20):5703-10. Cancer Res. 2002. PMID: 12384528

8

ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.

Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D. Yang W, et al. Among authors: klos ks. Cancer. 2003 Sep 15;98(6):1123-30. doi: 10.1002/cncr.11625. Cancer. 2003. PMID: 12973835 Free article.

9

ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.

Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. Yang W, et al. Cancer. 2002 Jun 1;94(11):2855-61. doi: 10.1002/cncr.10553. Cancer. 2002. PMID: 12115372 Free article.

10

Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells.

Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. Yao J, et al. Oncogene. 2001 Dec 6;20(56):8066-74. doi: 10.1038/sj.onc.1204944. Oncogene. 2001. PMID: 11781819

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters